AL
Alma Yesodot Ltd.
KVSR | TA
Overview
Corporate Details
- ISIN(s):
- IL0011731457
- LEI:
- Country:
- Israel
- Address:
- HaBarzel 3, 6971005 Tel Aviv - Jaffa
- Website:
- https://www.almayesodot.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kvasir focuses on developing innovative medical devices and diagnostic technologies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-24 17:08 |
Regulatory News Service
Opening of Trading on April 27 2025-ALMA YESODOT B1
|
Hebrew (modern) | 118.8 KB | ||
| 2025-04-23 11:59 |
Regulatory News Service
Identifying Details of New Security-ALMA YESODOT B1
|
Hebrew (modern) | 87.5 KB | ||
| 2024-11-05 15:46 |
Regulatory News Service
Changes in the company's name and security, effective as of November 7, 2024
|
Hebrew (modern) | 108.5 KB | ||
| 2024-10-29 18:37 |
Regulatory News Service
The sector classification of the company will be changed, as of October 31, 202…
|
Hebrew (modern) | 121.3 KB | ||
| 2024-10-29 17:20 |
Regulatory News Service
Base price of 1 agora and unlimited price fluctuation
|
Hebrew (modern) | 90.8 KB | ||
| 2023-05-22 23:20 |
Report Publication Announcement
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Hebrew (modern) | 174.5 KB | ||
| 2023-05-22 23:20 |
Pre-Annual General Meeting Information
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Russian | 46.0 KB | ||
| 2023-03-23 21:00 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 22.7
|
English | 1.2 MB | ||
| 2023-03-23 21:00 |
Legal Proceedings Report
Analysis update following financial report- price target is updated to NIS 22.7
|
Russian | 71.0 KB | ||
| 2022-12-11 20:40 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 32.9…
|
English | 1.2 MB | ||
| 2022-12-11 20:40 |
Business and Financial Review
Analysis update following financial report- price target is updated to NIS 32.9…
|
Russian | 67.3 KB | ||
| 2022-08-30 20:47 |
Investor Presentation
Analysis update report ,target price is at 47.6NIS
|
English | 1.2 MB | ||
| 2022-08-30 20:47 |
Business and Financial Review
Analysis update report ,target price is at 47.6NIS
|
Russian | 63.9 KB | ||
| 2022-08-18 16:58 |
Investor Presentation
Presentation
|
English | 3.0 MB | ||
| 2022-08-18 16:58 |
Pre-Annual General Meeting Information
Presentation
|
Russian | 42.7 KB |
Automate Your Workflow. Get a real-time feed of all Alma Yesodot Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Alma Yesodot Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alma Yesodot Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
United States of America
ENSC
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
United States of America
ENTX
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
United States of America
ENTO
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
United States of America
TRDA
South Korea
183490
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Sweden
ENZY
South Korea
446440
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Sweden
EQL
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
United States of America
EQ
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
United States of America
ERAS